CNS Drugs

, Volume 25, Issue 7, pp 555–573

Enhancing CNS Repair in Neurological Disease

Challenges Arising from Neurodegeneration and Rewiring of the Network


  • Xiaohua Xu
    • Department of NeurologyMayo Clinic and Foundation
  • Arthur E. Warrington
    • Department of NeurologyMayo Clinic and Foundation
  • Allan J. Bieber
    • Department of NeurologyMayo Clinic and Foundation
    • Department of NeurologyMayo Clinic and Foundation
    • Department of ImmunologyMayo Clinic and Foundation
Leading Article

DOI: 10.2165/11587830-000000000-00000

Cite this article as:
Xu, X., Warrington, A.E., Bieber, A.J. et al. CNS Drugs (2011) 25: 555. doi:10.2165/11587830-000000000-00000


Repair of the central nervous system (CNS) constitutes an integral part of treating neurological disease and plays a crucial role in restoring CNS architecture and function. Distinct strategies have been developed to reconstruct the damaged neural tissue, with many tested preclinically in animal models. We review cell replacement-based repair strategies. By taking spinal cord injury, cerebral ischaemia and degenerative CNS disorders as examples for CNS repair, we discuss progress and potential problems in utilizing embryonic stem cells and adult neural/non-neural stem cells to repair cell loss in the CNS. Nevertheless, CNS repair is not simply a matter of cell transplantation. The major challenge is to induce regenerating neural cells to integrate into the neural network and compensate for damaged neural function. The neural cells confront an environment very different from that of the developmental stage in which these cells differentiate to form interwoven networks.

During the repair process, one of the challenges is neurodegeneration, which can develop from interrupted innervations to/from the targets, chronic inflammation, ischaemia, aging or idiopathic neural toxicity. Neurodegeneration, which occurs on the basis of a characteristic vascular and neural web, usually presents as a chronically progressive process with unknown aetiology. Currently, there is no effective treatment to stop or slow down neurodegeneration. Pathological changes from patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis indicate a broken homeostasis in the CNS. We discuss how the blood-brain barrier and neural networks are formed to maintain CNS homeostasis and their contribution to neurodegeneration in diseased conditions.

Another challenge is that some inhibitors produced by CNS injury do not facilitate the regenerating neural cells to incorporate into a pre-existing network. We review glial responses to CNS injury. Of note, the reactive astrocytes not only encompass the lesions/pathogens but may also form glial scars to impede regenerating axons from traversing the lesions. In addition, myelin debris can prevent axon growth. Myelination enables saltatory transduction of electrical impulses along axonal calibers and actually provides trophic support to stabilize the axons. Therefore, repair strategies should be designed to promote axonal growth, myelination and modulate astrocytic responses. Finally, we discuss recent progress in developing human monoclonal IgMs that regulate CNS homeostasis and promote neural regeneration.

Copyright information

© Adis Data Information BV 2011